Cast will recreate memorable scenes from classic sitcom and share stories of beloved co-stars, Peter Boyle and Doris Roberts
Event Benefits the Peter Boyle Research Fund and Supports the Black Swan Research Initiative, IMF’s Signature Project Aimed at Finding the First Definitive Cure for Myeloma
The International Myeloma Foundation (IMF), celebrating their 30th anniversary as the first and largest myeloma-specific foundation in the world, today announced that Ray Romano and his “Everybody Loves Raymond” castmates will reunite for a special evening to honor co-star Peter Boyle and re-create scenes from the sitcom that ran from 1996-2005. In addition to Romano, Patricia Heaton, Brad Garrett, Monica Horan and co-creator and Executive Producer Phil Rosenthal will participate in the two-hour event, along with special guests and bonus content.
Proceeds from the event benefit the Peter Boyle Research Fund, named for the beloved actor who died in 2006 after a four-year battle with multiple myeloma – a complex and often misdiagnosed cancer of the plasma cells in the bone marrow. It is the second most common blood cancer in the world. Through laughter, the event honors Boyle and raises crucial funds to find a cure for myeloma. The Peter Boyle Research Fund has supported the IMF’s innovative research programs since the fund’s inception in 2007. For the 14th year, Loraine Alterman Boyle serves as Event Chair for the annual IMF Comedy Celebration in honor of her late husband. Since 2007, the annual event has featured more than 50 celebrity comedians and musical performers, and raised $8 million.
For the eighth year, the event also supports the International Myeloma Foundation’s signature Black Swan Research Initiative® (BSRI), a groundbreaking and collaborative global project aimed at developing the first definitive cure for myeloma. Led by a multinational consortium of leading myeloma experts, BSRI aims to treat myeloma early and aggressively through a broad range of simultaneous initiatives. One promising endeavor are the “Cure” trials, designed to achieve a dramatic benefit for patients with early disease. For additional information on BSRI, visit bsri.myeloma.org.